These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19815174)

  • 21. DES in CTO: cosmetic or clinical benefit.
    Goyal BK
    Catheter Cardiovasc Interv; 2009 May; 73(6):780. PubMed ID: 19370758
    [No Abstract]   [Full Text] [Related]  

  • 22. Study of restenosis in drug eluting stents: new insights from greyscale intravascular ultrasound and virtual histology.
    Garcia-Garcia HM; Shen Z; Piazza N
    EuroIntervention; 2009 May; 5 Suppl D():D84-92. PubMed ID: 19736078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy.
    Nfor T; Ansaarie I; Gupta A; Bajwa T; Allaqaband S
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):543-9. PubMed ID: 19405161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vessel diameter should be taken into account in saphenous stenting.
    Lozano I; Rondan J; Avanzas P
    EuroIntervention; 2010 Apr; 5(8):991-3. PubMed ID: 20542787
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study.
    Ko DT; Guo H; Wijeysundera HC; Zia MI; Džavík V; Chu MW; Fremes SE; Cohen EA; Tu JV
    JACC Cardiovasc Interv; 2011 Sep; 4(9):965-73. PubMed ID: 21939936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
    EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transition from bare metal to drug eluting stenting in contemporary US practice: effect on incidence and predictors of clinically driven target lesion revascularization.
    Jonas M; Resnic FS; Levin AD; Arora N; Rogers CD
    Catheter Cardiovasc Interv; 2007 Aug; 70(2):175-83. PubMed ID: 17630659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience.
    Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Vassilev D; Fraccaro C; Roncon L; Faggian G
    Cardiovasc Revasc Med; 2014 Mar; 15(2):76-9. PubMed ID: 24560299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
    Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
    JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients.
    Hakeem A; Helmy T; Munsif S; Bhatti S; Mazraeshahi R; Cilingiroglu M; Effat M; Leesar M; Arif I
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):343-55. PubMed ID: 21328679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of different re-stenting strategies on expansion of a drug-eluting stent implanted to treat bare-metal stent restenosis.
    Kalińczuk Ł; Demkow M; Mintz GS; Cedro K; Debski A; Ciszewski M; Ciszewski A; Kruk M; Karcz M; Warmiński G; Pregowski J; Chmielak Z; Witkowski A; Lubiszewska B; Ruzyłło W
    Am J Cardiol; 2009 Aug; 104(4):531-7. PubMed ID: 19660607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal revascularization strategies for percutaneous coronary intervention of distal anastomotic lesions after coronary artery bypass surgery.
    Badr S; Kitabata H; Dvir D; Torguson R; Barbash IM; Loh JP; Pichard AD; Waksman R
    J Interv Cardiol; 2013 Aug; 26(4):366-71. PubMed ID: 23795684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
    Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new ostial stent positioning system (Ostial Pro) for the accurate placement of stents to treat aorto-ostial lesions.
    Fischell TA; Malhotra S; Khan S
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):353-7. PubMed ID: 18288737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies.
    Alfonso F; Pérez-Vizcayno MJ; Hernandez R; Fernandez C; Escaned J; Bañuelos C; Bethencourt A; López-Mínguez JR; Angel J; Cequier A; Sabaté M; Morís C; Zueco J; Seabra-Gomes R;
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):459-67. PubMed ID: 18814274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-ST-segment elevation myocardial infarction related to vulnerable neoatheroma in bare-metal stents 2 years after percutaneous coronary intervention of a coronary saphenous vein graft.
    Roleder T; Wańha W; Smolka G; Ochała A; Wojakowski W
    JACC Cardiovasc Interv; 2014 Aug; 7(8):e95-6. PubMed ID: 25086848
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of drug-eluting stent restenosis.
    Ishikawa K; Aoyama Y; Hirayama H
    J Invasive Cardiol; 2012 Apr; 24(4):178-82. PubMed ID: 22477755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Compare drug-eluting stent to bare-metal stent in prognosis on treating diffuse coronary lesions].
    Qiao SB; Hou Q; Xu B; Chen J; Liu HB; Yang YJ; Wu YJ; Yuan JQ; Wu Y; Dai J; You SJ; Ma WH; Zhang P; Gao Z; Dou KF; Qiu H; Mu CW; Chen JL; Gao RL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jun; 34(6):487-91. PubMed ID: 16842660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DES in SVGs: safe and at least short-term effective.
    Hillegass WB
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):356-7. PubMed ID: 21328680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.